Skip to content


  • Short report
  • Open Access

The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice

Contributed equally
Cellular & Molecular Biology Letters201823:58

  • Received: 2 March 2018
  • Accepted: 22 November 2018
  • Published:



We investigated the suppressive effect of siRNA-mediated co-inhibition of PD-1 and CTLA-4 expression on H22 hepatomas in mice.


Murine H22 cells were cultured in vivo in ICR mice. An allograft tumor model was also established in another ICR mouse group. The tumor-bearing mice were randomly divided into four groups: control, single PD-1 siRNA, single CTLA-4 siRNA, and double PD-1 + CTLA-4 siRNAs. The survival time and physiological condition of the mice were observed after the injection of the siRNAs and placebo. The volume and weight of the solid tumor were measured to assess the inhibition of the tumor. To assess the effects of siRNAs on mouse immune function, the protein levels of IFN-γ and IL-10 in the blood and PD-L1 in the tumor and liver were determined using ELISA, and the mRNA levels of IFN-γ, PD-L1PD-1, CTLA-4, IL-6 and Survivin in the tumor, liver and spleen were determined using quantitative RT-PCR. The ratios of Bax and Bcl-2 protein were determined via western blot to analyze the effect of siRNAs on tumor cell apoptosis.


The anti-tumor effect appeared in all groups with siRNA-mediated inhibition. The tumor growth suppression was stronger in the group with double inhibition. The weight and volume of the tumors were significantly lower and the survival rate improved in the three siRNA groups. IFN-γ levels increased but IL-10 levels decreased in the blood of the siRNA group mice compared with the results for the control group. In the tumor and spleen tissue, the IFN-γ levels significantly increased, but in the liver tissue they significantly decreased in the three siRNA groups. The results of quantitative RT-PCR showed that the mRNAs for PD-1 and CTLA-4 were downregulated in spleen tissue in the three siRNA groups, while the PD-L1 mRNA and protein levels increased significantly in the tumor, but decreased in the liver. Survivin and IL-6 mRNA levels decreased in the tumor. Western blot results showed that ratio of Bax and Bcl-2 had significantly increased. These results indicated that downregulating PD-1 and CTLA-4 could increase the body’s immune response and promote apoptosis of tumor cells.


Co-inhibiting the expressions of PD-1 and CTLA-4 can effectively suppress the growth of H22 hepatoma and promote the apoptosis of tumor cells in mice. Blocking PD-1 and CTLA-4 can improve the vitality of T cells, and improve the immune environment and response.


  • PD-1
  • CTLA -4
  • H22
  • siRNA
  • Immune
  • IFN-γ


Cancer cells can often evade the immune system. The main factor enabling this escape ability is the presence of negative regulatory receptors on the T-cell surface [1]. Programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the most important of these negative regulatory receptors [2].

PD-1 is a member of the CD28 family. It is a type I transmembrane protein expressed on the surface of activated T-cell membranes [3]. The main ligands of PD-1 are PD-L1 (programmed cell death-ligand1) and PD-L2 (programmed cell death-ligand 2), which can interact with PD-1 to produce inhibitory signals, inhibit the activation and proliferation of T cells, and reduce the immune response to tumor cells [4].

CTLA-4 is a transmembrane protein encoded by the CTLA-4 gene, expressing in activated CD4+ (auxiliary) and CD8+ (cytotoxic) T cells. By binding with its ligand B7 molecules, CTLA-4 produces inhibitory signals and inhibits the activation of T cells [57] to protect the tumor cell from attack.

Therefore, blocking the ligand binding site or reducing the expression of PD-1 and CTLA-4 should stimulate the proliferation of immune cells and induces or enhances the anti-tumor immune response. A large number of experiments have proved this assumption. Blocking the PD-1/PD-L1 signaling pathway inhibited the growth of a variety of malignant tumors [8], and downregulation of CTLA-4 also showed great potential for tumor suppression.

Preclinical and clinical studies also show that the immune checkpoint therapy provides a survival benefit for some significant number of patients with liver cancer, and a combination of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies is an effective treatment strategy forhepatocellular carcinoma (HCC) [9, 10].

The usual method of blocking these signaling pathways is with an antibody or small chemical molecule. In this study, double-stranded interference RNA (siRNA) is applied to inhibit the expression of PD-1 and CTLA-4 to study the feasibility of siRNA as a therapeutic for liver cancer.

Experimental materials and methods

Animals and tumor cell lines

All the mice in study were male ICR (Institute of Cancer Research) mice, purchased from Beijing Vital Lihua with Certificate of Quality No. SCXK 2016–0011. They weighed 22–27 g at the time of purchase. The animals were housed individually in cages in a temperature-controlled room with a 12-h light/dark cycle. After one week of acclimation with free access to regular rodent chow and water, the mice were used for further experiments.

The H22 hepatocarcinoma cells were donated by Weifang Medical College. All the animal experimental procedures in this study were conducted in accordance with protocols approved by the Institutional Ethical Committee of Qingdao Medical University.

Modeling tumor-bearing mice

H22 hepatocarcinoma cells were injected into the peritoneal cavities of 48 mice and passaged three times in succession. Ascite buildup was visible 7–9 days later. The viscous ascite was extracted and the milk-white ascite was selected for the cell count. It was diluted to give a cell count of 1 × 107/ml. Each mouse was inoculated with 0.2 ml of the cell suspension into the right forelimb armpit [11].

Introduction of siRNA

After the tumor had grown for 6 days, the mice were randomly divided into four equal groups (n = 12): control, siPD-1, siCTLA-4 and siPD-1+ siCTLA-4 groups. Each group was given a different transfection reagent (Entranster-in-vivo, EngreenBiosystem Co., Ltd.) and different siRNA: negative control siRNA, siPD-1, siCTLA-4, or siPD-1 + siCTLA-4 (synthesized by Shanghai GenePharma Co., Ltd.). The transfection reagent (about 30 μl) and 19.8 μg siRNA were injected into each tumor once every 3 days for one month. Twenty-four hours after the last administration of the tested drug on day 30 of the experiment, blood samples were collected from the mice’s eyes. The serum was harvested by centrifugation. Then, all the mice were euthanized.

The sequence of siPD-1: sense:5′-CCUGGAGACCUCAACAAGAdTdT-3′, antisense: 5′-UCUUGUUGAGGUCUCCAGGdTdT-3′. The sequence of siCTLA-4: sense: 5′-GAUCCUUGUCGCAGUUAGCdTdT-3′, antisense: 5′-GCUAACUGCGACAAGGAUCdTdT-3′.The sequence of negative control siRNA: sense: 5’-UUCUCCGAACGUGUCACGUdTdT-3′, antisense: 5′-ACGUGACACGUUCGGAGAAdTdT-3′.

Observing the physiological condition of the H22 mice

The physiological condition of mice was assessed once every 4 days during the experiment. This included measuring the volume of the solid tumor,the mass of food intake, and the survival time. The calculation of the solid tumor volume was:
$$ \mathrm{V}=1/2\times {\left(\mathrm{a}\times \mathrm{b}\right)}^2 $$
where a and b represent the largest and the smallest diameters, respectively. The calculation of tumor growth inhibition rate was:
$$ \left(\mathrm{Control}\ \mathrm{tumor}\ \mathrm{weight}-\mathrm{Experimental}\ \mathrm{group}\ \mathrm{tumor}\ \mathrm{weight}\right)/\mathrm{Control}\ \mathrm{group}\ \mathrm{tumor}\times 100\% $$
The test continued for 30 days. Animals that lived more than 30 days were defaulted as 30 days. The survival rate was calculated as a percentage:
$$ \mathrm{Survival}\ \mathrm{rate}=\left\{\left(12\hbox{-} \mathrm{number}\ \mathrm{of}\ \mathrm{mice}\ \mathrm{that}\ \mathrm{died}\ \mathrm{in}\ \mathrm{each}\ \mathrm{group}\right)/12\right\}\times 100\% $$

Determining the levels of IFN-γ, IL-10 and PD-L1

After siRNAs were injected for one month, blood was taken from the eyeball of the mice and kept at room temperature for 1 h to precipitate the blood cells. The serum (supernatant) was obtained by centrifugation at 5000 rpm for 10 min.

The interferon gamma (IFN-γ) and interleukin 10 (IL-10) levels in the serum were determined using an ELISA kit according to the manufacturer’s instructions (cat. no. ELM-IFNg and ELM-IL10, RayBiotech).

The PD-L1 protein level in the tumor and liver tissue was also assayed via ELISA. Samples of 100 mg tumor or liver tissue were taken from each mouse, washed bloody with phosphate buffer saline (PBS), and then placed in 1 ml PBS for homogenization. The homogenate was stored at − 20 °C overnight, then centrifuged at 1000 g for 10 min. The precipitate was discarded and the supernatant was retained. The PD-L1 protein in the supernatant was assayed with an ELISA kit according to the manufacturer’s instructions (cat. no. CSB-EL004911MO, Wuhan Huamei Biotechnology Co., Ltd.).

Determining the mRNA levels of IFN-γ, PD-1, CTLA-4, Survivin and, IL-6

Quantitative RT-PCR was used to determine the mRNA expression levels of IFN-γ, IL-6, PD-L1 and Survivin in the tumor, IFN-γ, PD-L1 in the liver and IFN-γ, PD-1 and CTLA-4 in the spleen. Tissue samples were taken. The tissue was partly excisedand total RNA was extracted with Trizol reagent (Takara Company). cDNA was obtainedwith a reverse transcription kit (TransGen Biotech), amplified via quantitative PCR (TransGen Biotech). The reaction conditions were 94 °C for 30s, 94 °C for 5 s and 60 °C for 30s, for forty cycles. Three parallel reactions were performed for each sample. The 2-Ct method was used to calculate the expression of each mRNA in each mouse. The primer sequences are shown in Table 1.
Table 1

Primer sequences for PCR

Gene name

Primer sequence



















Determining the expressions of Bax and Bcl-2

Western blot was used to determine the expression levels of Bax and Bcl-2. Samples of tumor tissue (50 mg) were taken from each mouse and put in 400 μl of RIPA buffer with 1% PMSF. The protein was extracted using aconventional method. The concentration of protein was determined via the BCA method and adjusted to the same concentration for every sample.

30 μg (about 6 μl) of protein was separated using 15% SDS-PAGE, then transferred onto PVDF membrane under 300 mA of current for 2 h. The membrane was blocked with 5% skimmed milk at room temperature for 2 h, thenincubated with the primary antibodies (anti-Baxdiluted 1:200 andanti-Bcl-2diluted 1:200, Santa Cruz Biotechnology, Inc.; and anti-β-actindiluted 1:700, Zhongshan Bio-Tech Co., Ltd.) at 4 °C overnight. The membrane was taken out, washed with TBST 3 times, and incubated withthe secondary antibody (anti-mouse antibody, diluted 1:7000, MultiSciences) at room temperature for 1 h, followed by 3 washes with TBST, each for 10 min.

Through the development of ECL hypersensitive luminescent liquid (chemiluminescent HRP Substrate), the gray value of the gel image was analyzed using the appropriate software. The expressions of Bax and Bcl-2 were determined based on the ratio of the Bax and Bcl-2 protein gray values.

Statistical analysis

The results are expressed as means ±SD. The differences were determined using the ANOVA test, except for the survival rate, which was determined using the Logrank-test.A value less than 0.05 (p < 0.05) was considered statistically significant. The statistical analyses were performed using the GraphPad Prism 6.0 statistical software package.


Physiological observations

In the first 5 days after inoculation with H22 cells, the mice maintained a good living condition. Their hair remained bright in color and there was no significant difference between the groups. After 5 days, small nodules appeared in all the groups of mice. As the experiment progressed, the tumor in the single siRNA groups grew more slowly than in the control group. The slowest growth was seen in the PD-1 + CTLA-4 siRNA group. The mice in the control group displayed a gradual dimming of hair color and loss of appetite. They also exhibited abnormal activity.

The inhibitory effect of siRNA on the tumor

The volumes and weights of the tumor in the siRNA groups were significantly below those of the control group, with the most pronounced effect in the double siRNA group (p < 0.05). The results are shown in Table 2 and Fig. 1.
Table 2

The tumor inhibition rate for each siRNA (mean ± SD, n = 12)



Tumor weight (g)

Inhibition rate (%)



6.9075 ± 2.71



1.7067 ± 0.65*




1.7144 ± 0.39*


siPD-1 + siCTLA-4


0.7440 ± 0.15*


*p < 0.05 vs.the control group

Fig. 1
Fig. 1

The antitumor effect of siPD-1 and siCTLA-4 in the H22 allograft. CT = control, siPD-1 = group injected with siRNA for PD-1, siCTLA-4 = group injected with siRNA for CTLA-4, siPD-1 + siCTLA-4 = group injected with siRNA for PD-1 + CTLA-4. a –Photo of four representative tumor-bearing mice (one per group). The picture was taken 30 days after inoculation with H22 cells. b – Photo of 5 solid tumors from each group. Tumors were removed from mice 30 days after inoculation with H22 cells. c – Change curve of tumor volume. Tumor diameter was measured with a caliper once every 4 days for 30 days and volume was calculated as described in section observing the physiological condition of the H22 mice 2.4. d – Survival rate of mice. These results indicate that siRNAs markedly inhibited the growth of tumor

The effect of siRNA on IFN-γ, IL-10 and PD-L1 levels in the blood and tissue

ELISA was employed to analyze the levels of IFN-γ, IL-10 and PD-L1. The results show that the IFN-γ level in the blood of the siRNA group mice had increased, while the level of the cytokine IL-10 had significantly decreased (p < 0.05) compared with the control group. The PD-L1 level had significantly increased in the tumor, but significantly decreased in the liver compared with the control group (p < 0.05, Fig. 2).
Fig. 2
Fig. 2

IFN-γ, IL-10 and PD-L1 levels in the blood and tissue. These results are based on ELISA tests. CT = control, siPD-1 = group injected with siRNA for PD-1, siCTLA-4 = group injected with siRNA for CTLA-4, siPD-1 + siCTLA-4 = group injected with siRNA for PD-1 + CTLA-4. a – IFN-γlevel in mouse serum. b – IL-10 level in mouse serum. c – PD-L1 level in tumor tissue. d – PD-L1 content in liver tissue. The expressions of IFN-γ, IL-10 and PD-L1 in the blood and tissue of the siRNA groups were significantly different from those in the control group (**p < 0.01, *p < 0.05)

The effect of siRNA onthe mRNA of IFN-γ, PD-L1, PD-1, CTLA-4, IL-6 and Survivinin the tissue

The effects of siRNAs on the mRNA of IFN-γ, PD-1, PD-L1, CTLA-4 and Survivin in the tumor, liver and spleen were determined using quantitative RT-PCR. The results showed that the mRNA levels of IFN-γ and PD-L1 in the tumor of the siRNA groups had significantly increased compared with the control group (p < 0.05).Survivin and IL-6 expression had decreased (p < 0.05). Compared with the control group, the expressions of PD-L1 and IFN-γ in the liver had decreased (p < 0.05). The mRNA levels of PD-1 and CTLA-4 had decreased, but IFN-γ had increased in the spleen (p < 0.05) compared with the control group.

These results indicate that PD-1 siRNA and CTLA-4 siRNA could enhance the immune response of mice and inhibit the expressions of some oncogenes. Interestingly, the expression of PD-L1 increased in the tumor. This phenomenon may be attributed to a compensation effect in the organism. When PD-1 was downregulated, the tumor cells attempted to utilize the PD-1/PD-L1 pathway to escape the immune cell attack and express more PD-L1, so the mRNA level of PD-L1 increased (Fig. 3).
Fig. 3
Fig. 3

PCR results for PD-1, PD-L1, CTLA-4, IFN-γ, IL-6 and Survivin mRNA in various tissues. CT = control, siPD-1 = group injected with siRNA for PD-1, siCTLA-4 = group injected with siRNA for CTLA-4, siPD-1 + siCTLA-4 = group injected with siRNA for PD-1 + CTLA-4. a – Level of IFN-γ mRNA in the tumors. b – Level of Survivin mRNA in the tumors. c – Level of PD-L1 mRNA in the tumors. d – Level of IL-6 mRNA in the tumors. e – Level of PD-1 mRNA in the spleen. f – Level of CTLA-4 mRNA in the spleen. g – Level of IFN-γ mRNA in the spleen. h – Level of IFN-γ mRNA in the liver. i – Level of PD-L1 mRNA in the liver. The mRNA expressions of some genes in the siRNA groups were significantly different than those in the control group (*p < 0.05, **p < 0.01)

The effect of siRNA on Bax and Bcl-2 in the tumor

The tumor Bax and Bcl-2 levels were determined via western blotting. The ratio of Bax to Bcl-2 increased in siPD-1, siCTLA-4 and siPD-1 + siCTLA-4 groups (p < 0.05) compared to the levels for the control group (Fig. 4).
Fig. 4
Fig. 4

Bax and Bcl-2 assays. The levels of Bax and Bcl-2 were determined using western blot. a – Photo of the western blot gels for the four tumor samples. CT = control, siPD-1 = group injected with siRNA for PD-1, siCTLA-4 = group injected with siRNA for CTLA-4, siPD-1 + siCTLA-4 = group injected with siRNA for PD-1 + CTLA-4. b – Quantitative analysis of Bax and Bcl-2 expressions. Compared with the control group, the Bax-to-Bcl-2 ratio significantly increased in all siRNA groups (**p < 0.01, *p < 0.05)


PD-1 is mainly expressed in activated T cells, where its function is to inhibit their excessive activation. This is a normal self-stabilizing mechanism of the immune system [12]. Its ligand, PD-L1, is mainly expressed on the surface of tumor cells [13]. The tumor microenvironment can induce infiltrating T cells to express PD-1. When PD-1 and PD-L1 interact, the PD-1/PD-L1 signaling pathway maintains the activation. In this case, the activation of T lymphocytes is inhibited, and tumor cells escape immune surveillance [1416]. siRNA can block the PD-1 pathway, partially restoring the function of T cells, so that they can continue to kill tumor cells [17].

Both CD28 and CTLA-4 are expressed on the surface of T cells. They competitively bind with CD80 (B7–2) and CD86 (B7–1) [18], but their functions are distinct. The main function of CD28 is to participate in the activation of T cells [19]. CTLA-4 is an immunosuppressive receptor, but it has a stronger affinity with the two ligands than CD28 [20].

The interaction of CTLA-4 and its ligands generates an inhibitory signal and decreases or represses the viability of T cells [21].Blocking the interaction of CTLA-4 and ligandspromotes CD28 to bind the two ligands, activates T cells, improves the body’s immune response, and kills tumor cells. An existing study shows that inhibiting the binding of CTLA-4 and its ligands also can downregulate Bcl-2 and promote the apoptosis of tumor cells.

IFN-γ is produced by T cells. It can directly inhibit the proliferation of tumor cells [22], increase the expression of surface MHC antigen and tumor necrosis factor (TNF), and play an important role in anti-tumor angiogenesis. IFN-γ can also regulate the expression of Fas/FasL in tumor cells and enhance the sensitivity of tumor cells to the Fas-mediated apoptosis pathway, reducing the ability of tumor cells to evade attack by the immune system. Therefore, enhancing T-cell activity increases the release of IFN-γ and produces astronger inhibitory effect on the tumor [23].

IL-10 is a cytokine that regulates immune function, acting on a variety of immune cell subsets and playing a role in immune suppression in a variety of ways that can cause or prevent tumor immune escape. Recent studies reported that IL-10 also stimulates the immune response, suggesting that it is a multifunctional cytokine with positive and negative regulatory effects [24].

IL-6 is a multifunctional inflammatory cytokine with an important role in inflammation and tumorigenesis. It is also an important tumor-promoting cytokine that enhances proliferation and anti-apoptotic effects in tumor cells [25]. Furthermore, IL-6 levels in cancer tissues and serum are elevated in HCC patients. They correlate with tumor metastasis and reduced patient survival rate [26]. The expression of IL-6 mRNA decreased in our experiment, leading to an inhibition of proliferation and increase in apoptosis of tumor cells.

Our study mainly applied RNAi technology with the aim of blocking the two signaling pathways. PD-1/PD-L1and CTLA-4/CD80, /CD86 were used to enhance the activity of T cells to inhibit the growth of tumor cells. Mice were inoculated with H22 tumor cells to yield the tumor model, and then siRNAs were injected into the tumor.

Our results indicate that the siRNAs blocking the two signaling pathways could significantly improve the immune response in the mice. They show that tumor growth was significantly inhibited and that the expression of PD-1 and CTLA-4 in the tumor tissue significantly decreased after the introduction of siPD-1 and siCTLA-4. The expressions of IFN-γ obviously increased in the blood, tumor and spleen in the siRNA groups, but decreased in the liver. The IL-10 level in the blood decreased in the siRNA groups. The reduction in the IFN-γ mRNA level in the livers of the siRNA group mice could be a protective effect of siRNA on the liver tissue, reducing the inflammation reaction.

The expressions of PD-L1 in the livers of siRNA group mice were significantly lower than those for the control group mice. The expressions of PD-L1 were mainly on the surface of the tumor cells, rather than in the normal tissue. In this study, there was a high expression level in control group, but very low in the siRNA groups. The results indicated that H22 hepatoma cells had metastasized to the liver in the control group, but not in the siRNA groups. siRNAs blocking the PD-1/PD-L1 or CTLA-4/CD80, /CD86 pathways could reduce the metastasis of tumor cells.

Interestingly, when the PD-1 signaling pathway was blocked, the expression of PD-L1 increased in the tumor. This phenomenon may be due to the tumor cells attempting to employ PD-1/PD-L1 signaling pathway to escape the attack by the immune cells and enhance the expressions of PD-L1. This would increase the mRNA and protein levels of PD-L1. This is a compensation effect.

Survivin is an inhibitor of apoptosis. It only expresses in tumor and embryonic tissues [27]. Survivin is closely related to the differentiation, proliferation, invasion and metastasis of tumor cells [28]. The results of this study indicate that the expression of survivin in the siRNA groups was significantly lower than that in the control group. The reduction in the surviving level was consistent with the promotion of tumor cell apoptosis.

Bax and Bcl-2 are a pair of important apoptosis-related proteins in the body. Any increase in the level of Bax or decrease in the level of Bcl-2 can promote tumor cell apoptosis, so Bax/Bcl-2 clearly have a close relationship to the genesis and development of tumors [29]. Our results show that the level of Bcl-2 was lower and that of Bax was higher when PD-1 or CTLA-4 were downregulated. This result is consistent with previous reports and it proves again that blocking the PD-1/PD-L1 or CTLA-4/CD80, /CD86 pathways could promote the apoptosis of tumor cells [30].

Overall, downregulation of PD-1 or CTLA-4 had a significant inhibitory effect on the growth of the tumor. Double downregulation of PD-1 and CTLA-4 had a more obvious effect than single gene downregulation.

Currently, most targeted immunotherapy drugs are antibodies or small molecule drugs [31]. Small molecule drugs are generally chemical substances that are difficult to metabolize into nontoxic water and CO2 and can have toxic side effects on the body. Antibody-based immunotherapies have some disadvantages, such as their high cost, limited half-life, and immunogenicity. Our aim is to find an alternative method to effectively inhibit the proliferation of tumor cells but with fewer side effects.

siRNA synthesis is easy, low cost, and will not lead to an immune response. On the other hand, siRNA is a biological molecule, easy to metabolize, and has no side effect on the body. Our results indicate that siRNA can be applied to inhibit tumor growth and could be developed into an RNAi-based immunotherapy or even a precision medicine for tumors.


In the study, we knocked down the expressions of PD-1 and CTLA-4 using siRNA. Our result show that the growth of tumor cells was significantly inhibited in siRNA groups. When the two signaling pathways of PD-1/PD-L1 and CTLA-4/CD80, /CD86were blocked, the vitality of T cells was enhanced, and the antitumor immune response of the body increased. This promoted the apoptosis of H22 hepatoma cells and reduced the metastasis of tumor cells. Simultaneous knockdown of PD-1 and CTLA-4 to inhibit proliferation of H22 hepatoma cell was more effective than single knockdown of PD-1 or CTLA-4 and did not appear to be toxic. Co-inhibiting oncogene expression is an attractive potential treatment for cancer.



CD4+/CD8 +: 

Auxiliary T cells/cytotoxic T cells


Cytotoxic T lymphocyte antigen 4


Enzyme-linked immunosorbent assay


Interferon gamma


Interleukin 10




Programmed cell death protein-1


Protease inhibitor


Rapid cell and tissue lysate


Double-stranded interference RNA


Interference RNA PD-1


Interference RNA CTLA-4


sodium dodecyl sulfate Polyacrylamide gel electrophoresis





This work was supported by Shandong Province Science Funding (2014GGH218023).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

YG designed this study. LL and KG performed the experiments. LL, KG and FZ analyzed the data. LL wrote the manuscript. KG and YG modified the manuscript. All the authors read and approved the final manuscript.

Ethics approval

All the animal experimental procedures in this study were performed in accordance with the Declaration of Helsinki and conducted according to protocols approved by the Institutional Ethical Committee of Qingdao Medical University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Biochemistry and Molecular Biology, Medical College, Qingdao University, 38 Dengzhou Road, Qingdao, 266021, Shandong, China
Central Laboratory, Binzhou People’s Hospital, Binzhou, 256610, Shandong, China
Integrative Medicine Research Center, Medical College, Qingdao University, Qingdao, 266021, Shandong, China
Department of Biochemistry and Molecular Biology, Heze Medical College, Heze, 274000, Shandong, China


  1. Li S, Yang F, Ren X. Immunotherapy for hepatocellular carcinoma. Drug Discov Ther. 2015;9:363–71.View ArticleGoogle Scholar
  2. Kasamatsu T, Ino R, Takahashi N, Gotoh N, Minato Y, Takizawa M, et al. PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia. Br J Haematol. 2018;180:705–14.View ArticleGoogle Scholar
  3. Elhag OA, Hu XJ, Wenying Z, Li X, Yuan YZ, Deng LF, et al. Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity. Asian Pac J Cancer Prev. 2012;13:4031–6.View ArticleGoogle Scholar
  4. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111–22.View ArticleGoogle Scholar
  5. Guntermann C, Alexander DR. CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr (319) phosphorylation: a potential role for tyrosine phosphatases. J Immunol. 2002;168:4420–9.View ArticleGoogle Scholar
  6. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. Molecular basis of T cell inactivation by CTLA-4. Science. 1998;282:2263–6.View ArticleGoogle Scholar
  7. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332, 600:–609.Google Scholar
  8. Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013;12:631–45.View ArticleGoogle Scholar
  9. Kudo M. Immuno-oncology in hepatocellular carcinoma: 2017 update. Oncology. 2017;93(Suppl 1):147–59.View ArticleGoogle Scholar
  10. Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37:110–22.View ArticleGoogle Scholar
  11. Li W, Xu Q, He YF, Liu Y, Yang SB, Wang Z, et al. Anti-tumor effect of steamed Codonopsis lanceolata in H22 tumor-bearing mice and its possible mechanism. Nutrients. 2015;7:8294–307.View ArticleGoogle Scholar
  12. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319–22.View ArticleGoogle Scholar
  13. He L, Zhang G, He Y, Zhu H, Zhang H, Feng Z. Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res. 2005;25:3309–13.PubMedGoogle Scholar
  14. Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. Proc Natl Acad Sci U S A. 2008;105:15016–21.View ArticleGoogle Scholar
  15. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089–96.PubMedGoogle Scholar
  16. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Emma J, Taylor M, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.View ArticleGoogle Scholar
  17. Hirayama Y, Gi M, Yamano S, Tachibana H, Okuno T, Tamada S, et al. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma. Cancer Sci. 2016;107:1736–44.View ArticleGoogle Scholar
  18. Egen JG, Allison JP, Cytotoxic T. Lymphocyte Antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002;16:23–35.View ArticleGoogle Scholar
  19. Jackson SR, Yuan J, Teaque RM. Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy. 2014;6:833–52.View ArticleGoogle Scholar
  20. Brzostek J, Gascoigne NRJ, Rybakin V. Cell type-specific regulation of immunological synapse dynamics by B7 ligand recognition. Front Immunol. 2016;7:24–39.View ArticleGoogle Scholar
  21. Dustin ML. The immunological synapse. Cancer Immunol Res. 2014;2:1023–33.View ArticleGoogle Scholar
  22. Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM. IFN-λ cancer immunotherapy: new kid on the block. Immunotherapy. 2016;8:877–88.View ArticleGoogle Scholar
  23. Shih KS, Lin CC, Hung HF, Yang YC, Wang CA, Jeng KC, et al. One-step chromatographic purification of helicobacter pylori neutrophil-activating protein expressed in Bacillus subtilis. PLoS One. 2013;8:e60786.View ArticleGoogle Scholar
  24. Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, et al. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib. Hematol Oncol. 2016;35:711–8.View ArticleGoogle Scholar
  25. Rusolo F, Pucci B, Colonna G, Capone F, Guerriero E, Milone MR, et al. Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines. Molecules. 2013;18:2549–62.View ArticleGoogle Scholar
  26. Park HJ, Kusnadi A, Lee EJ, Kim WW, Cho BC, Lee IJ, et al. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol. 2012;278:76–83.View ArticleGoogle Scholar
  27. Zaffaroni N, Pennati M, Folini M. Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs. Methods Mol Biol. 2007;361:239–63.PubMedGoogle Scholar
  28. Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL, et al. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem. 2008;105:381–90.View ArticleGoogle Scholar
  29. Ge YL, Zhang X, Zhang JY, Hou L, Tian RH. The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int Immunopharmacol. 2009;9:389–95.View ArticleGoogle Scholar
  30. Sun LM, Liu YC, Li W, Liu S, Liu HX, Li LW, et al. Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression. Eur Rev Med Pharmacol Sci. 2017;21:1198–205.PubMedGoogle Scholar
  31. Guzik K, Zak KM, Grudnik P, Magiera K, Musielak B, Törner R, et al. Small-molecule inhibitors of the programmed cell Death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1. J Med Chem. 2017;13:5857–67.View ArticleGoogle Scholar


© The Author(s) 2018